首页> 美国卫生研究院文献>Springer Open Choice >Determination of cystathionine beta-synthase activity in human plasma by LC-MS/MS: potential use in diagnosis of CBS deficiency
【2h】

Determination of cystathionine beta-synthase activity in human plasma by LC-MS/MS: potential use in diagnosis of CBS deficiency

机译:LC-MS / MS测定人血浆中胱硫醚β-合酶活性:可用于诊断CBS缺乏症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cystathionine β-synthase (CBS) deficiency is usually confirmed by assaying the enzyme activity in cultured skin fibroblasts. We investigated whether CBS is present in human plasma and whether determination of its activity in plasma could be used for diagnostic purposes. We developed an assay to measure CBS activity in 20 μL of plasma using a stable isotope substrate - 2,3,3-2H serine. The activity was determined by measurement of the product of enzyme reaction, 3,3-2H-cystathionine, using LC-MS/MS. The median enzyme activity in control plasma samples was 404 nmol/h/L (range 66–1,066; n = 57). In pyridoxine nonresponsive CBS deficient patients, the median plasma activity was 0 nmol/ho/L (range 0–9; n = 26), while in pyridoxine responsive patients the median activity was 16 nmol/hour/L (range 0–358; n = 28); this overlapped with the enzyme activity from control subject. The presence of CBS in human plasma was confirmed by an in silico search of the proteome database, and was further evidenced by the activation of CBS by S-adenosyl-L-methionine and pyridoxal 5′-phosphate, and by configuration of the detected reaction product, 3,3-2H-cystathionine, which was in agreement with the previously observed CBS reaction mechanism. We hypothesize that the CBS enzyme in plasma originates from liver cells, as the plasma CBS activities in patients with elevated liver aminotransferase activities were more than 30-fold increased. In this study, we have demonstrated that CBS is present in human plasma and that its catalytic activity is detectable by LC-MS/MS. CBS assay in human plasma brings new possibilities in the diagnosis of pyridoxine nonresponsive CBS deficiency.Electronic supplementary materialThe online version of this article (doi:10.1007/s10545-010-9178-3) contains supplementary material, which is available to authorized users.
机译:通常通过测定培养的皮肤成纤维细胞中的酶活性来确认胱硫醚β-合酶(CBS)的缺乏。我们调查了人体血浆中是否存在CBS,以及测定其在血浆中的活性是否可用于诊断目的。我们开发了一种测定方法,使用稳定的同位素底物-2,3,3- 2 H丝氨酸来测定20μL血浆中的CBS活性。活性通过使用LC-MS / MS测量酶反应产物3,3- 2 H-胱硫醚来确定。对照血浆样品中的酶活性中位数为404 nmol / h / L(范围66–1,066; n = 57)。在吡ido醇反应迟钝的CBS缺乏患者中,血浆活性中位数为0 nmol / ho / L(范围0-9; n = 26),而在吡ido醇反应敏感的患者中,中位数活性为16 nmol / hour / L(范围0-358; n = 28);这与对照对象的酶活性重叠。通过计算机搜索蛋白质组数据库,证实了人血浆中CBS的存在,并进一步通过S-腺苷-L-蛋氨酸和吡ido醛5'-磷酸对CBS的激活以及检测到的反应的构象进一步证明了产物3,3- 2 H-胱硫醚,与先前观察到的CBS反应机理一致。我们假设血浆CBS酶起源于肝细胞,因为肝氨基转移酶活性升高的患者血浆CBS活性增加了30倍以上。在这项研究中,我们已经证明人血浆中存在CBS,并且其催化活性可以通过LC-MS / MS检测到。人血浆中的CBS分析为吡ido醇无反应的CBS缺乏症的诊断带来了新的可能性电子补充材料本文的在线版本(doi:10.1007 / s10545-010-9178-3)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号